Antibody-Oligonucleotide Conjugates (AOCs)

ADC-Related Custom Services

Antibody-Oligonucleotide Conjugate (AOC) consists of three parts: antibody, linker and oligonucleotide. AOC combines the tissue-specific targeting of antibody drugs with the target-specific capabilities of small nucleic acids, addressing the limitation of current small nucleic acid drugs that mainly target the liver through LNP and GalNAc delivery systems.

References:

[1]. Dugal-Tessier J, Thirumalairajan S, Jain N. Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates. J Clin Med. 2021;10(4):838. [Content Brief]

Antibody-Oligonucleotide Conjugates (AOCs) Related Products (7):

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-P990051

Delpacibart
Delpacibart is a humanized IgG1 kappa antibody targeting TFRC. Delpacibart is commonly used for synthesizing AOC drugs such as Delpacibart etedesiran. Delpacibart is commonly used in the study of type 1 myotonic dystrophy (DM1).

HY-177566

Delpacibart braxlosiran
Delpacibart braxlosiran (Del-brax), an antibody oligonucleotide conjugate (AOC), consists of a monoclonal antibody (Delpacibart) (HY-P990051) that binds to the transferrin receptor 1 (TfR1) conjugated with a siRNA targeting DUX4 (Double homeobox protein) mRNA. It is used for the study of Facioscapulohumeral Muscular Dystrophy (FSHD). The abnormal expression of DUX4 protein leads to changes in gene expression in muscle cells that are associated with the life-long, progressive loss of muscle function in patients with FSHD.

HY-177568

Mozistobart zoratolimod
Mozistobart zoratolimod is an antibody-oligonucleotide conjugate (AOC) composed of a humanized monoclonal antibody (HY-P990930 Mozistobart) targe ting CD22 linked to a TLR9 agonist. It is used for the study of cancer immunotherapy.

HY-177565

Delpacibart etedesiran
Delpacibart braxlosiran (Del-desiran), an antibody oligonucleotide conjugate (AOC), consists of a monoclonal antibody (Delpacibart) (HY-P990051) that binds to the transferrin receptor 1 (TfR1) conjugated with a siRNA targeting DMPK (DM1 protein kinase) mRNA. Delpacibart braxlosiran is used for the study of myotonic dystrophy type 1 (DM1).

HY-177484

Rostudirsen
Rostudirsen, one of the components of Zeleciment rostudirsen (HY-177485), is a phosphorodiamidate morpholino oligomer. Zeleciment rostudirsen consists of Rostudirsen (HY-177484) conjugated to a fragment antibody (Fab), Zeleciment (HY-P990780), which binds to the transferrin receptor 1 (TfR1) that is highly expressed in muscle. It is designed to enable targeted muscle tissue delivery and promote exon skipping in the nucleus, allowing muscle cells to create internally shortened, near full-length dystrophin protein.

HY-177453

Basivarsen
Basivarsen (DYNE-101 oligomer) is composed of an antisense oligonucleotides and a linker (HY-177454). It is designed to target mutant nuclear myotonic dystrophy protein kinase (DMPK) RNA for RHase H-mediated degradation to correct splicing. It is used for the study of myotonic dystrophy type 1 (DM1).

HY-P990780

Zeleciment		98.85%
Zeleciment is an anti-TFRC IgG1κ monoclonal antibody.

Name
Email *

	Sorry, but the email address you supplied was invalid.